Abstract

Cell death mechanisms in T lymphocytes vary according to their developmental stage, cell subset and activation status. The cell death control mechanisms of mucosal-associated invariant T (MAIT) cells, a specialized T cell population, are largely unknown. Here we report that MAIT cells express key necroptotic machinery; receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like (MLKL) protein, in abundance. Despite this, we discovered that the loss of RIPK3, but not necroptotic effector MLKL or apoptotic caspase-8, specifically increased MAIT cell abundance at steady-state in the thymus, spleen, liver and lungs, in a cell-intrinsic manner. In contrast, over the course of infection with Francisella tularensis, RIPK3 deficiency did not impact the magnitude of the expansion nor contraction of MAIT cell pools. These findings suggest that, distinct from conventional T cells, the accumulation of MAIT cells is restrained by RIPK3 signalling, likely prior to thymic egress, in a manner independent of canonical apoptotic and necroptotic cell death pathways.

Details

Title
RIPK3 controls MAIT cell accumulation during development but not during infection
Author
Patton, Timothy 1   VIAFID ORCID Logo  ; Zhao, Zhe 2   VIAFID ORCID Logo  ; Lim, Xin Yi 2 ; Eddy, Eleanor 2 ; Wang, Huimeng 3 ; Nelson, Adam G. 2 ; Ennis, Bronte 2 ; Eckle, Sidonia B. G. 2 ; Souter, Michael N. T. 2 ; Pediongco, Troi J. 2 ; Koay, Hui-Fern 2 ; Zhang, Jian-Guo 4 ; Djajawi, Tirta M. 5 ; Louis, Cynthia 4   VIAFID ORCID Logo  ; Lalaoui, Najoua 4   VIAFID ORCID Logo  ; Jacquelot, Nicolas 4 ; Lew, Andrew M. 4 ; Pellicci, Daniel G. 6 ; McCluskey, James 2 ; Zhan, Yifan 7 ; Chen, Zhenjun 2 ; Lawlor, Kate E. 8   VIAFID ORCID Logo  ; Corbett, Alexandra J. 2   VIAFID ORCID Logo 

 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d) 
 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072) 
 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Department of Immunology and Microbiology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Royal Children’s Hospital Parkville, Murdoch Children’s Research Institute, Parkville, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346); University of Melbourne, Department of Paediatrics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Shanghai Huaota Biopharm, Department of Drug Discovery, Shanghai, China (GRID:grid.1008.9) 
 Hudson Institute of Medical Research, Centre for Innate Immunity and Infectious Diseases, Clayton, Australia (GRID:grid.452824.d); Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Department of Molecular and Translational Science, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
Pages
111
Publication year
2023
Publication date
Feb 2023
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2775341207
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.